Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103740 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
A Phase 3 study of Paget's Disease of Bone, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
- 20
- Study locations
NCT00103740 is a Phase 3 study of Paget's Disease of Bone that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 185 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT00103740, a Phase 3 study of Paget's Disease of Bone, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this core study was to show non-inferiority of zoledronic acid to risedronate, with respect to the proportion of patients who achieved therapeutic response. The extended observation period included participants of the core study who responded to treatment.
Conditions Studied
Interventions
- DRUG Risedronate
- DRUG zoledronic acid
- DRUG placebo to zoledronic acid
- DRUG Placebo to risedronate
- DRUG Calcium and vitamin D supplements
Study Locations (20)
Other
- Novartis Investigative Site - Fitzroy
- Novartis Investigative Site - Kogarah
- Novartis Investigative site - Newcastle
- Novartis Investigative Site - Parkville
- Novartis Investigative site - St Leonards
- Novartis Investigative site - Brussels
- Novartis Investigative Site - Ghent
- Novartis Investigative Site - Montreal
- Novartis Investigative Site - Angers
- Novartis Investigative Site - Dreux
Arizona
- Novartis Investigative site - Tucson
Colorado
- Novartis Investigative Site - Colorado Springs
Indiana
- Novartis Investigative Site - Indianapolis
Louisiana
- Novartis Investigative Site - New Orleans
Massachusetts
- Novartis Investigative Site - Boston
New York
- Novartis Investigative Site - Syracuse
Ohio
- Novartis Investigative Site - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2002-04 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103740
The ClinicalTrials.gov registry entry for NCT00103740 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paget's Disease of Bone appearing as the primary indexed condition, and to 5 interventions - of which Risedronate is the first listed.
NCT00103740 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT00103740 about?
NCT00103740 is a clinical study titled "Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period". The primary objective of this core study was to show non-inferiority of zoledronic acid to risedronate, with respect to the proportion of patients who achieved therapeutic response. The extended observation period included participants of the core study who responded to treatment.
What is the current status of trial NCT00103740?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2002-04. Estimated completion is 2011-04.
What conditions does trial NCT00103740 study?
This clinical trial studies the following conditions: Paget's Disease of Bone.
What interventions are being tested in trial NCT00103740?
The interventions under investigation include: Risedronate (DRUG), zoledronic acid (DRUG), placebo to zoledronic acid (DRUG), Placebo to risedronate (DRUG), Calcium and vitamin D supplements (DRUG).
Who is sponsoring clinical trial NCT00103740?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00103740 being conducted?
This trial has 20 study locations across Arizona, Colorado, Indiana, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.